On these pages you can check out the latest breast cancer news from BCAC and our member groups. We also provide up-to-date information and links to current breast cancer research and clinical trials. Read latest stories below, or use the filters or the pager below for other stories. Use the form to the right of this to subscribe to our e-News.
Taking hormone drugs for more than ten years could help to dramatically reduce the risk of breast cancer recurrence, according to a landmark study.
A randomised clinical trial involving nearly 2,000 women found that cancer recurrence dropped by a third in those who took hormone drugs for ten years rather than the standard five.
Researchers hope that three new breakthrough drugs designed to target triple negative breast cancer could potentially transform therapy for those with the hard-to-treat disease.
There are currently no targeted therapies for those with triple negative breast cancer leaving medical care reliant on traditional treatments such as chemotherapy and radiotherapy.
Scientists say they now have a near-perfect picture of the genetic events that cause breast cancer.
The study, published in Nature, has been described as a "milestone" moment that could help unlock new ways of treating and preventing the disease.
The largest study of its kind unpicked practically all the errors that cause healthy breast tissue to go rogue.
A new study shows that post-menopausal women who stayed on a low fat diet for around eight years had improved breast cancer survival rates compared with women who were not on a low fat diet.
The Los Angeles Biomedical Research Institute study was presented at the American Association for Cancer Research Annual Meeting.
Women in Auckland who have received treatment for early stage breast cancer are needed for a trial investigating whether a Mediterranean diet improves health outcomes.
The trial is the first of its kind in New Zealand and is run by the Department of Nutrition at the University of Auckland.
The Breast Cancer Aotearoa Coalition (BCAC) is calling for urgent action following three recent studies which highlight inequalities in access to screening and treatment for Māori women with breast cancer.
The three studies, all published this year, show that Māori women have higher rates of advanced cancer; experience longer delays in getting surgical treatment; and have lower rates of breast cancer screening.
A Waikato study has found that Māori women wait longer for breast cancer surgery than New Zealand European women.
The longer delays for treatment are thought to be a significant contributing factor in the lower survival rates for Māori women compared with non-Māori in New Zealand.
A recent study has found concerns about fertility stop one third of young women with breast cancer from taking tamoxifen despite its known benefit in reducing the risk of breast cancer returning.
The study, which was published in the Journal of the National Cancer Institute also found one quarter of women who started taking tamoxifen stopped taking it before the recommended treatment period ended.
New research from two studies has found postmenopausal patients with early stage breast cancer who take two types of drugs, aromatase inhibitors (such as Letrozole or Anastrozole) together with bisphosphonates, have better survival rates than those who don’t.
Results from the two studies were collated by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) group in the UK and published recently in The Lancet medical journal.
The latest innovation in fighting cancer has come to New Zealand and will be trialled in breast cancer patients from this month.
Immunotherapy, which is being used successfully to treat patients with melanoma, will now be trialled in patients with Triple Negative Breast Cancer (TNBC), a rare and aggressive form of breast cancer.